Research Institute of Molecular Pathology (IMP)
David Drechsel, the Head of Protein Technologies at Vienna BioCenter Core Facilities (VBCF) GmbH, has a comprehensive background in biochemistry and cell biology. With years of experience at various research institutes and educational institutions, David has proven to be a skilled and dedicated professional in the field. Currently holding the title of Service and Facility Leader at Max-Planck-Institute of Molecular Cell Biology and Genetics, David continues to contribute significantly to the scientific community.
Research Institute of Molecular Pathology (IMP)
The Research Institute of Molecular Pathology (IMP) in Vienna is a basic biomedical research institute largely sponsored by Boehringer Ingelheim. With over 200 scientists from 40 countries, the IMP is committed to scientific discovery of fundamental molecular and cellular mechanisms underlying complex biological phenomena. Research areas include cell and molecular biology, microscopy, immunology and cancer, developmental biology, chromosome biology, and computational biology.